Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_assertion type Assertion NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_head.
- NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_provenance.
- NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_assertion evidence source_evidence_literature NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_provenance.
- NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_assertion SIO_000772 23888070 NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_provenance.
- NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_assertion wasDerivedFrom befree-2016 NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_provenance.
- NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_assertion wasGeneratedBy ECO_0000203 NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_provenance.